Variable (reference) | Progression-free survival | Overall survival | ||
HR (95% CI) | P value | HR (95% CI) | P value | |
White race (nonwhite) | 0.179 (0.049 to 0.663) | 0.010 | 0.127 (0.0277 to 0.586) | 0.008 |
Metastasis at diagnosis (no metastasis) | 0.399 (0.129 to 1.227) | 0.109 | 0.628 (0.222 to 1.773) | 0.380 |
ICB monotherapy (ICB plus other) | 2.153 (0.613 to 7.557) | 0.231 | 8.146 (1.680 to 39.510) | 0.009 |
Ipilimumab plus nivolumab (ICB plus other) | 5.326 (1.77 to 16.045) | 0.003 | 11.598 (3.016 to 44.598) | <0.001 |
CHN (soft tissue or visceral) | 0.164 (0.042 to 0.638) | 0.009 | 0.197 (0.057 to 0.685) | 0.011 |
Non-CHN (soft tissue or visceral) | 0.284 (0.066 to 1.221) | 0.091 | 0.546 (0.115 to 2.579) | 0.445 |
P values in bold are statistically significant per the pre-specified threshold of P < 0.05.
CHN, cutaneous angiosarcoma of the head and neck; ICB, immune checkpoint blockade; OS, overall survival; PFS, progression-free survival.